Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHA:688016)

Market Cap	10.80B +2.9%
Revenue (ttm)	1.39B +17.6%
Net Income	588.53M +31.5%
EPS	4.88 +34.8%
Shares Out	120.84M
PE Ratio	18.30
Forward PE	17.17
Dividend	2.30 (2.59%)
Ex-Dividend Date	Jun 5, 2026

Volume	1,615,249
Open	90.48
Previous Close	88.80
Day's Range	88.00 - 91.25
52-Week Range	84.53 - 124.30
Beta	0.17
Analysts	Buy
Price Target	127.25 (+42.43%)
Earnings Date	Aug 26, 2026

About SHA:688016

Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft system; Cratos and Castor, a branched aortic stent graft system; Talos, a thoracic stent graft system; and Hercules, a thoracic stent graft system with low ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2012
• Employees: 822
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688016

Financial Performance

In 2025, SHA:688016's revenue was 1.35 billion, an increase of 11.96% compared to the previous year's 1.21 billion. Earnings were 563.33 million, an increase of 12.19%.

Analyst Summary

According to 6 analysts, the average rating for 688016 stock is "Buy." The 12-month stock price target is ¥127.25, which is an increase of 42.43% from the latest price.

Price Target

¥127.25

(42.43% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 24, 2026

Data Sources Report a data error